Purpose To assess adjustments in retinal nonperfusion (RNP) in sufferers with retinal vein occlusion (RVO) treated with ranibizumab (RBZ) Design Supplementary outcome measure in randomized double-masked handled clinical trial Subjects Thirty-nine sufferers with central RVO (CRVO) and 42 with branch RVO (BRVO) Methods Topics were randomized to 0. 2.0mg RBZ for six months there was… Continue reading Purpose To assess adjustments in retinal nonperfusion (RNP) in sufferers with